Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma

Fujimura, Taku; Sato, Yasufumi; Kambayashi, Yahiko; Tanita, Kayo; Tsukada, Akira; Terui, H.; Hashimoto, Akira; Aiba, Setsuya

doi:10.1111/bjd.16676

Cited by 12 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, MMP9 remodels the extracellular matrix and promotes the sprouting and growth of new blood vessels [19] and, as we have previously reported, most cutaneous angiosarcomas produce MMP9 [20]. Since CXCL10 was reported as a predictive biomarker for cutaneous angiosarcoma [21], IL-17 might play a similar role in the tumor microenvironment of angiosarcoma-like BP.…”

Section: Discussionmentioning

confidence: 62%

IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation

et al. 2020

View full text Add to dashboard Cite

Stewart-Treves syndrome (STS) is a rare cutaneous lymphangiosarcoma developing from chronic lymph edema as a consequence of radical mastectomy or surgical invasion of the groin for the treatment of cervical or penile cancer. Previous reports suggested possible mechanisms in the development of lymphangiosarcoma that correlate with the immunological background of STS patients. In this report, we described two cases of STS developing in patients who underwent radical dissection for cervical cancer, we employed immunohistochemical staining of IL-23 and IL-17. Case ReportCase 1 A 79-year-old Japanese woman visited our outpatient clinic with a 1-month history of a red, easy to bleed, nodule on the right femur. She had undergone resection of a cervical cancer 24 years before and developed prominent lymph edema in the lower extremities. During her initial visit, physical examination revealed a dark-red nodule with extended purpura on the right femur together with prominent lymph edema (Fig. 1a). Histologically, these were irregularly anastomosing vascular channels lined by single layers of enlarged, atypical endothelial cells that existed between the collagen bundles (Fig. 1b). Immunohistochemical staining revealed that these atypical endothelial cells were positive for vimentin, CD31, CD34, D2-40, and Factor VIII. The Ki67 score was 90%. Moreover, a substantial number of IL-23-producing cells (Fig. 1c) as well as IL-17-producing cells (Fig. 1d) were detected at the edge of the tumor mass. Positron emission tomography scans showed no evidence of metastases. From the

show abstract

Section: Discussionmentioning

confidence: 62%

IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In aggregate, TAM were reported as an optimal target for immunotherapy, 6 and TAMrelated products could even be biomarkers for the efficacy and immune related adverse events in cancer patients. [9][10][11] In this report, we describe two cases in which DT therapy for advanced melanoma failed but were successfully controlled by nivolumab monotherapy. The antitumor effects of nivolumab after DT therapy may be augmented by M1-polarized TAM induced by nivolumab.…”

Section: Discussionmentioning

confidence: 96%

“…reported that reprogramming TAM into inflammatory phenotypes by targeting CD40 and CD115 suppresses melanoma growth in vivo . In aggregate, TAM were reported as an optimal target for immunotherapy, and TAM‐related products could even be biomarkers for the efficacy and immune related adverse events in cancer patients …”

Section: Discussionmentioning

confidence: 99%

Two cases of dabrafenib and trametinib therapy‐failed advanced melanoma successfully controlled by nivolumab monotherapy

Sato

Fujimura

Kambayashi

et al. 2018

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Although therapies for advanced melanoma have been greatly improved by the development of immune checkpoint inhibitors and BRAF/mitogen-activated protein kinase kinase inhibitors, there are still many concerns about the administration of these novel drugs. Therefore, to combine these therapies sequentially at appropriate time points of the disease is important. In this report, we report two cases in which dabrafenib and trametinib therapy for advanced melanoma failed but were successfully controlled by nivolumab monotherapy, and investigated the sera sCD163, CCL22 and CXCL10 as biomarkers for tumor progression. Interestingly, the sera levels of sCD163, CXCL10 and CCL22, both of which are produced by activated tumor-associated macrophages, were increased in parallel with the tumor progression in each case. Because this report presents only two cases, further data will need to be accumulated to provide more fundamental insights into the usefulness of these biomarkers for predicting disease progression in melanoma.

show abstract

“…This study by Fujimura et al . in the British Journal of Dermatology gives an interesting and important suggestion on managing refractory cutaneous angiosarcoma (CAS) using the new drug eribulin . CAS is widely known to be a rare malignant tumour that mainly affects the scalp of the elderly and has a very poor prognosis.…”

mentioning

confidence: 99%

“…Fujimura et al . capitalized on this to report their experience with three cases . The effectiveness varied, but they did not encounter critical adverse effects.…”

mentioning

confidence: 99%

Can we manage refractory cutaneous angiosarcoma?

Hata

2018

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma

Cited by 12 publications

References 14 publications

IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation

IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation

Two cases of dabrafenib and trametinib therapy‐failed advanced melanoma successfully controlled by nivolumab monotherapy

Can we manage refractory cutaneous angiosarcoma?

Contact Info

Product

Resources

About